Literature DB >> 29230668

Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.

Kai Wang1, Yinyan Wang2,3, Xing Fan3, Yanong Li4, Xing Liu3, Jiangfei Wang2, Lin Ai1, Jianping Dai4, Tao Jiang5,6,7.   

Abstract

In this study we aimed to identify the anatomic features of 1p/19q co-deletion and investigate the predictive values of tumor location and radiological characteristics for the survival of anaplastic oligodendroglial (AO) glioma patients. Voxel-based lesion-symptom mapping (VLSM) analysis was applied to define the brain regions associated with occurrence of 1p/19q co-deletion in a cohort of 206 AO tumor patients (discovery set) treated between May 2009 and September 2013. Retrospectively, the acquired clusters and radiological features were subjected to Kaplan-Meier survival analysis using data from the Chinese Glioma Genome Atlas (validation set) to evaluate their prognostic role in AO patients. The institutional review board approved this study. The right frontal lobe and right anterior insular lobe were specifically associated with high occurrence of 1p/19q co-deletion. For AO tumors not involving these areas, the absence of contrast enhancement predicted longer progression-free (p = 0.018) and overall survival (p = 0.020); moreover, in patients with contrast enhancement, edema could stratify the survival outcome (p = 0.013 for progression-free survival, p = 0.016 for overall survival). For AO tumors located in the VLSM-identified regions, edema was also able to stratify the survival outcome of patients without contrast enhancement (p = 0.025 for progression-free survival, p = 0.028 for overall survival). The 1p/19q co-deletion showed predilection for specific brain regions. According to the tumor involvement of VLSM-identified regions associated with 1p/19q co-deletion, radiological features were predictive for AO patient survival outcomes.

Entities:  

Keywords:  1p/19q; Anaplastic; Oligodendroglial; Radiology; Survival outcome

Mesh:

Year:  2017        PMID: 29230668     DOI: 10.1007/s11060-017-2673-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Voxel-based lesion-symptom mapping.

Authors:  Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

2.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

3.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Authors:  M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Pathology and biology guidelines for resectable and unresectable neuroblastic tumors and bone marrow examination guidelines.

Authors:  P F Ambros; I M Ambros
Journal:  Med Pediatr Oncol       Date:  2001-12

Review 5.  Genetics of adult glioma.

Authors:  McKinsey L Goodenberger; Robert B Jenkins
Journal:  Cancer Genet       Date:  2012-12-11

6.  Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.

Authors:  Michael D Jenkinson; Daniel G du Plessis; Trevor S Smith; Kathy A Joyce; Peter C Warnke; Carol Walker
Journal:  Brain       Date:  2006-05-02       Impact factor: 13.501

Review 7.  Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Authors:  Michael Weller; Roger Stupp; Monika E Hegi; Martin van den Bent; Joerg C Tonn; Marc Sanson; Wolfgang Wick; Guido Reifenberger
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

8.  Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?

Authors:  S Fellah; D Caudal; A M De Paula; P Dory-Lautrec; D Figarella-Branger; O Chinot; P Metellus; P J Cozzone; S Confort-Gouny; B Ghattas; V Callot; N Girard
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-06       Impact factor: 3.825

9.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

10.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

View more
  2 in total

Review 1.  Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis.

Authors:  Beverly I De Leeuw; Kirsten M Van Baarsen; Tom J Snijders; Pierre A J T Robe
Journal:  Neurooncol Adv       Date:  2019-10-01

2.  Preoperative Radiomics Analysis of 1p/19q Status in WHO Grade II Gliomas.

Authors:  Ziwen Fan; Zhiyan Sun; Shengyu Fang; Yiming Li; Xing Liu; Yucha Liang; Yukun Liu; Chunyao Zhou; Qiang Zhu; Hong Zhang; Tianshi Li; Shaowu Li; Tao Jiang; Yinyan Wang; Lei Wang
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.